Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 21 of 6351
-
Could a stem cell transplant free kidney recipients from a lifetime of anti-rejection drugs?
Disease control Recruiting nowThe study will determine whether patients with functioning Human Leukocyte Antigen (HLA) matched kidney transplants for at least one year and who want to discontinue immunosuppressive drugs can be treated with Total Lymphoid Irradiation (TLI) and rabbit Anti-Thymocyte Globulin (r…
Phase 1 • Sponsor: Stephan Busque • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug aims to outperform standard therapy in High-Risk breast cancer
Disease control OngoingThis study aims to Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants with Residual Invasive Disease Following Neoadjuvant Therapy,This study will examine SHR-A1811versus trastuzumab emtansine (T-DM1) in p…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could brain implants tame severe mental illness?
Disease control Recruiting nowThis is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of combo-stim deep brain stimulation for treatment-refractory mental disorders (obsessive-compulsive disorder, schizophrenia, bipolar with depression, anorexia nervosa, gambl…
Sponsor: Shanghai Mental Health Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can an mRNA vaccine shield the most vulnerable from RSV?
Vaccine CompletedThe study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received s…
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 22, 2026 00:00 UTC
-
Aiming to cure esophageal cancer without the knife
Cure OngoingThe present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment o…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
Experimental malaria vaccine aims to block parasite growth
Vaccine CompletedMalaria is a major public health problem. There were around 240 million cases of malaria and 627,000 deaths worldwide in 2020. There is a great need for a safe, effective malaria vaccine and the team at University of Oxford is trying to make vaccine(s) which can prevent serious i…
Phase 1/2 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jul 22, 2026 00:00 UTC
-
Can whole blood beat component transfusions in trauma?
Disease control Recruiting nowThe goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who re…
Phase 3 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Double-Barreled CAR t attack shows promise for tough childhood leukemia
Disease control Recruiting nowThis study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).
Phase 1/2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
Cure Recruiting nowEnrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFO…
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
New TB vaccine aims to prevent active lung disease in adults
Vaccine OngoingThis study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active non-HIV-associated pulmonary tuberculosis. The study is di…
Phase 3 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: Vaccine
Last updated Jul 08, 2026 00:00 UTC
-
Mind-Reading implant aims to give a voice to the paralyzed
Knowledge-focused Recruiting nowThe CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Can adding radiation boost immunotherapy against spread head and neck cancer?
Disease control Recruiting nowStudy to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head \& neck cancers
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Twice-Yearly shot could revolutionize HIV prevention for young women
Prevention OngoingThe goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW). The primary objective of this study is to evaluate the efficacy of LE…
Phase 3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
Engineered immune cells take on tough lymphomas
Disease control Recruiting nowDALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymp…
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a Self-Amplifying mRNA vaccine outsmart COVID-19?
Vaccine CompletedThe purpose of this study is to assess the safety, reactogenicity and immune response of a self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike antigen (CoV-2 SAM \[LNP\] vaccine) in ascending doses w…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Aug 26, 2026 00:00 UTC
-
Can engineered immune cells tackle brain lymphoma?
Disease control OngoingThis research is being done to test the safety and effectiveness of axicabtagene ciloleucel (axi-cel), an anti-CD19 directed chimeric antigen receptor (CAR) T-cell therapy in treating relapsed/refractory central nervous system (CNS) lymphoma, systemic lymphoma with concurrent CNS…
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Four-Drug cocktail aims to crush myeloma before transplant
Disease control OngoingThis protocol is a phase III study designed to compare the efficacy and the safety of Isa-KRd induction, transplant, Isa-KRd post ASCT consolidation and Isa-KRd light consolidation vs KRd induction, transplant, KRd post ASCT consolidation and KRd light consolidation After confirm…
Phase 3 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New 9-Valent HPV vaccine aims to block more Cancer-Causing viruses
Vaccine OngoingThis phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.
Phase 3 • Sponsor: Xiamen University • Aim: Vaccine
Last updated Jun 27, 2026 07:58 UTC
-
Can a cancer drug stop the body from making extra bone?
Disease control OngoingThis is a phase 2 study, designed as a European multicentre 6-month double blind random-ized controlled trial (RCT) of AZD0530 versus matched placebo, followed by a 12 month trial comparing open-label extended AZD0530 treatment with historical control data. Study population: Mal…
Phase 2 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can an old malaria drug help fight severe COVID-19?
Disease control CancelledThe Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents. Approximately 25% of hospitalized patients require treatment in intensive…
Phase 3 • Sponsor: Apsen Farmaceutica S.A. • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC